Moreover, KYNA-pretreated MSCs can further boost TSG-6 production, and thus enhance the therapeutic capacity of human MSCs against lipopolysaccharide (LPS)-induced acute lung injury (37). This evidence concerns the gene TNFAIP6 and acute lung injury.